GPNMB: a potent inducer of immunosuppression in cancer.
Anna-Maria LazaratosMatthew G AnnisPeter M SiegelPublished in: Oncogene (2022)
The immune system is comprised of both innate and adaptive immune cells, which, in the context of cancer, collectively function to eliminate tumor cells. However, tumors can actively sculpt the immune landscape to favor the establishment of an immunosuppressive microenvironment, which promotes tumor growth and progression to metastatic disease. Glycoprotein-NMB (GPNMB) is a transmembrane glycoprotein that is overexpressed in a variety of cancers. It can promote primary tumor growth and metastasis, and GPNMB expression correlates with poor prognosis and shorter recurrence-free survival in patients. There is growing evidence supporting an immunosuppressive role for GPNMB in the context of malignancy. This review provides a description of the emerging roles of GPNMB as an inducer of immunosuppression, with a particular focus on its role in mediating cancer progression by restraining pro-inflammatory innate and adaptive immune responses.
Keyphrases
- poor prognosis
- immune response
- papillary thyroid
- free survival
- long non coding rna
- squamous cell
- end stage renal disease
- squamous cell carcinoma
- small cell lung cancer
- chronic kidney disease
- childhood cancer
- ejection fraction
- newly diagnosed
- lymph node metastasis
- dendritic cells
- young adults
- peritoneal dialysis
- anti inflammatory